Your Questions (and Criticisms) of Our Recent...

Here’s a shocking number: One out of eight American adults is taking a GLP-1, like Ozempic or Zepbound, according to a KFF poll. GLP-1s are the biggest pharmaceutical story since antidepressants. But there’s still so much we don’t know. “We’re only at the beginning of what’s been ...  Show more

In the U.S., illiberalism is in power. I don’t think anybody really argues against that. But I’ve been surprised by how weak liberalism has felt in response. Donald Trump isn’t a popular president; he isn’t making people want more of what he is. But if the forces of illiberalism ...  Show more

This week, we’re sharing a great conversation Ross had on “The Ezra Klein Show” this past spring. Ezra asks Ross about his most recent book, “Believe: Why Everyone Should Be Religious.” But along the way, they debate not just how religion influences the Trump administration bu ...

Once a year Matt and Sam take questions from listeners—and they always prove to be incredibly smart and interesting. This time around was no different, with questions that include such topics as: the crisis in Israel and Palestine, the influence of postliberal thinkers on the ...

The Times Opinion columnist Nick Kristof weighs in on the uncertainties following the United States’ surprise bombing of Iran and Tehran’s retaliation. “President Trump thinks that this is going to be successful and worth it, but the enemy gets a vote as well,” Kristof caution ...

Plus, why you’re wrong about your Zodiac sign.

On Today’s Episode:

How JPMorgan Enabled the Crimes of Jeffrey Epstein, by David ...